scholarly journals Clinical Efficacy of Topical Nasal Pomegranate Fruit Extract for Chronic Rhinitis and Chronic Rhinosinusitis

2021 ◽  
pp. 014556132110442
Author(s):  
Asaf Israeli ◽  
Golda Grinblat ◽  
Isaac Shochat ◽  
Miri Sarid ◽  
Mickey Dudkiewicz ◽  
...  
Keyword(s):  
Chronic Rhinosinusitis ◽  
Clinical Efficacy ◽  
Nasal Polyposis ◽  
Randomized Study ◽  
Nasal Discharge ◽  
Fruit Extract ◽  
Chronic Rhinitis ◽  
Falling Asleep ◽  
Double Blinded ◽  
Pomegranate Fruit

Objective: To evaluate the clinical efficacy of topical nasal Pomegranate Fruit Extract (PFE) for Chronic Rhinitis (CR), Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), and Chronic Rhinosinusitis without Nasal Polyposis (CRSsNP). Methods: Prospective, double-blinded, randomized study including 111 consecutive patients, between April 2012 and January 2017, afflicted by CRSwNP, CRSsNP, and CR. Patients from each group were randomly assigned to either PFE treatment or placebo twice daily for 30 days. Therapeutic efficacy was assessed by Ear Nose and Throat, blood and tomographic examinations, and the SNOT-20 questionnaire. Results: CR patients treated with PFE suffered significantly less from thick nasal discharge, difficulty falling asleep, reduced productivity, reduced concentration, and sadness ( P = .004, P = .02, P = .03, P = .007 and P = .02, respectively). Conclusions: Topical nasal PFE was found to have some benefits for CR patients, however, not for CRS with or without Nasal Polyposis.

scholarly journals Real-Life Experience of Monoclonal Antibody Treatments in Chronic Rhinosinusitis with Nasal Polyposis

2021 ◽  
Vol 182 (8) ◽  
pp. 736-743
Author(s):  
Eva C. Meier ◽  
Peter Schmid-Grendelmeier ◽  
Urs C. Steiner ◽  
Michael B. Soyka
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Rhinosinusitis ◽  
Successful Treatment ◽  
Nasal Polyposis ◽  
Real Life ◽  
Predictive Biomarkers ◽  
Sinus Surgery ◽  
Nasal Discharge ◽  
Eosinophilic Cationic Protein ◽  
Cationic Protein

<b><i>Introduction:</i></b> Few studies assess biologicals such as, omalizumab, mepolizumab, benralizumab, and dupilumab in patients suffering from chronic rhinosinusitis with nasal polyposis (CRSwNP). The reported success rate in these studies differ, and it remains uncertain if there are any biomarkers to predict successful therapy. Our aim was to analyze the therapeutic outcome in a real life setting and to identify predictive biomarkers for successful treatment. <b><i>Methods:</i></b> Data from patients with CRSwNP treated with a monoclonal antibody between November 2014 and January 2020 were analyzed retrospectively. Improvement in the polyp score and clinical symptoms like nasal obstruction, sense of smell, nasal discharge, and facial pain were evaluated. Other characteristics, including use of nasal or systemic steroids, comorbidities, previous history of sinus surgery, eosinophilia tissue, blood values (eosinophils, total immunoglobulin E, eosinophilic cationic protein, and interleukin 5), and allergic sensitization in serum were also investigated to identify possible predictive biomarkers. <b><i>Results:</i></b> Forty-eight treatments in 29 patients (m/f = 15/14) aged 27–70 years were reviewed. Treatments with mepolizumab showed the best success rates (78.9%), followed by omalizumab (50%) and benralizumab treatments (50%). However, a correlation between biomarkers and treatment success could not be found. <b><i>Discussion/Conclusion:</i></b> Treatment of CRSwNP with biologicals is a promising option for severe cases not responding to conventional therapy, including difficult-to-treat patients. Predictive biomarkers for a successful treatment could not be identified, but the reduction of eosinophilic cationic protein was linked with the response.

scholarly journals Long-Term Clinical Follow-Up of Patients With Chronic Rhinosinusitis

2020 ◽  
pp. 000348942096282
Author(s):  
Ulrica Thunberg ◽  
Amanj Saber ◽  
Bo Söderquist ◽  
Svante Hugosson
Keyword(s):  
Quality Of Life ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyposis ◽  
Nasal Congestion ◽  
Symptom Relief ◽  
Nasal Discharge ◽  
Long Term Follow Up

Objective: This study comprised a long-term follow-up of a cohort of patients with chronic rhinosinusitis (CRS) regarding clinical features and symptomatology. Methods: Data from 42 patients with CRS were available from a previous study. Forty of these patients were alive and were contacted for inclusion after approximately 10 years. Patients completed a questionnaire about disease and symptoms, and underwent a clinical examination. Results: Thirty-four patients (85%) responded and could be included and evaluated. For the participants in this follow-up study median length of time between initial inclusion (C1) and follow-up (C2) was 11 years (range: 8-15). In some patients the CRS shifted phenotype over time, from CRS with nasal polyposis to CRS without nasal polyposis or vice versa. The median total visual analogue score for combined sinonasal symptoms for all patients was statistically significantly reduced at follow-up. For individual patients, scores for nasal congestion, nasal discharge, facial pressure, and hyposmia were also statistically significantly reduced. The most frequently reported symptom-relieving treatments were nasal steroids and saline rinsing of the nose. Self-reported general quality of life was statistically significantly improved at C2 compared to C1. Conclusion: At long-term follow-up, symptoms were generally reduced and patients reported an improved quality of life. Patients can be given hope for eventual symptom relief. CRS is a chronic condition that seems to harbor the ability to alter its phenotype after several years. Topical corticosteroids and saline rinsing of the nose should be emphasized, since patients consider these treatments to be of high value.

Comparison of Efficacy of Mometasone Furoate versus Clarithromycin in the Treatment of Chronic Rhinosinusitis without Nasal Polyps in Chinese Adults

2011 ◽  
Vol 25 (6) ◽  
pp. e203-e207 ◽  
Author(s):  
Ming Zeng ◽  
Xiao-Bo Long ◽  
Yong-Hua Cui ◽  
Zheng Liu
Keyword(s):  
Chronic Rhinosinusitis ◽  
Clinical Efficacy ◽  
Nasal Polyps ◽  
Observation Time ◽  
Mometasone Furoate ◽  
Nasal Discharge ◽  
Chinese Adults ◽  
Open Label ◽  
Significant Difference ◽  
Physical Findings

Background Although both nasal steroids and macrolide antibiotics have been recommended for the treatment of chronic rhinosinusitis without nasal polyps (CRSsNPs), whether there is any difference in their clinical efficacy remains unexplored. In addition, few studies have investigated their clinical efficacy in a Chinese population living in China, who present distinct inflammatory patterns compared with white patients in western countries. This study compares the efficacy of mometasone furoate and clarithromycin treatment in CRSsNP in Chinese adults in a preliminary prospective, open-label, randomized trial. Methods Forty-three CRSsNP patients were randomized to receive mometasone furoate nasal spray at 200 μg (n = 21) or clarithromycin tablet at 250 mg (n = 22) once daily for 12 weeks. Patients were assessed before the treatment and after 4, 8, and 12 weeks after treatment. Subjective symptoms were scored on a visual analog scale. Endoscopy physical findings were scored according to Lanza-Kennedy scoring system. Moreover, smoking and atopic status and coexistence of allergic rhinitis (AR) and asthma were recorded. Results Before the treatment, no significant difference in symptoms and nasal endoscopic physical findings were found between mometasone furoate and clarithromycin group. As early as 4 weeks after dosing, a significant reduction of total symptom scores, nasal obstruction, headache, rhinorrhea and overall burden scores, and mucosal swelling and nasal discharge scores were observed in both groups. No significant difference in symptom or endoscopic scores was observed between these two groups at any posttreatment observation time point. The coexistence of AR was correlated with lower scores of mucosal edema and nasal secretion in the mometasone furoate group after 12-week treatment. Conclusion Mometasone furoate and clarithromycin show a comparable clinical effect for CRSsNPs in Chinese adults. Mometasone furoate is more effective in improving edema and secretion for CRSsNP patients with concomitant AR.

Postoperative application of amphotericin B nasal spray in chronic rhinosinusitis with nasal polyposis. Can recidive polyposis be prevented?

2008 ◽  
Vol 149 (37) ◽  
pp. 1737-1746 ◽  
Author(s):  
Imre Gerlinger ◽  
András Fittler ◽  
Anna Mayer ◽  
Ágnes Patzkó ◽  
Fruzsina Fónay ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Chronic Rhinosinusitis ◽  
Nasal Spray ◽  
Nasal Polyposis

A krónikus rhinosinusitis (KRS) a felnőttpopuláció 1–4%-át érintő, jelentős életminőség-romlást okozó idült, multifaktoriális, gyakran orrpolipképződéssel járó, etiológiáját illetően azonban pontosan nem tisztázott megbetegedés. Az elmúlt évtizedben felmerült, hogy az orrüregi nyálkahártya jellegzetes eozinofil sejtes beszűrődését okozó megbetegedésnek az orrüregi nyákban található gombák elleni fokozott – nem IgE típusú klasszikus allergiás – immunválasz a kiváltó oka. Célkitűzés: Ha igaz ez a feltételezés, akkor kézenfekvőnek tűnik, hogy az endoszkópos orrpolypectomiákat követően megfelelő ideig és koncentrációban adott amphotericin B-tartalmú orrspray kedvező hatású lehet a betegek számára, akár csökkentve a recidívák számát. Módszer: A feltételezés igazolá­sára a szerzők 33 beteg bevonásával prospektív, randomizált, placebokontrollált, kettős vak klinikai tanulmányt végeztek. A tanulmányt végül 30 beteg fejezte be. A 2005. november 1-je és 2006. október 1-je között orrpolyposissal endoszkópos műtétre került betegek egyik csoportja (A csoport, 14 beteg) egy évig 5 mg/ml koncentrációjú amphotericin B-tartalmú orrsprayt kapott, míg a placebo­csoport (B csoport, 16 beteg) hatóanyag nélküli orrsprayt. Az eredmények értékeléséhez a módosított Lund–Mackay-féle CT-értékelő pontrendszert, a tüneti változásokat vizsgáló pontrendszert (SNAQ-11), életminőségtesztet és endoszkópos kiértékelést végeztek. A műtétek előtt és a műtéteket követően egy évvel elvégzett vizsgálatok eredményeit SPSS 14.0 for Windows program segítségével értékelték. Eredmények: Az A csoport betegeinek CT-értékelő pontrendszere egy év elteltével jelentős szórást mutatott, a javulás jelei nélkül. A B csoportban a CT-értékelő pontrendszere enyhe javulást mutatott, azonban ez az A csoporttal összehasonlítva nem volt szignifikáns (p = 0,052). A tüneti változásokat vizsgáló pontrendszer (SNAQ-11), valamint az életminőségteszt mindkét betegcsoportban lényeges javulást mutatott, a két tesztben a változások mértékét összehasonlítva azonban egyik betegcsoport javára sem találtak szignifikáns különbséget. Az endoszkópos lelet az amphotericin B-csoport javára mutatott mérsékelt javulást 12 hónappal a műtéteket követően. Következtetések: A szerzők megállapítják, hogy az orrpolyposis miatt operált betegekben az amphotericin B-tartalmú orrcsepp egy évig történő adása nem okoz szignifikáns változást a CT-pontszámok, a klinikai tünetek, valamint az életminőség vonatkozásában. A betegek endoszkópos követése során az amphotericin B-csoportban észlelt kedvezőbb kép a klinikai tünetek javulásában nem nyilvánult meg. A szerzők a tanulmány eredményeiből levont tanulságok tükrében tárgyalják a gombaelméletről rendelkezésre álló eddigi ismeretanyagot. Kritikusan elemzik az elmúlt években publikált 7, ellentmondásos konklúziót mutató klinikai tanulmány tapasztalatait is.

scholarly journals Spontaneous Preterm Birth: Is Prevention with Aspirin Possible?

2021 ◽  
Author(s):  
Richard Berger ◽  
Ioannis Kyvernitakis ◽  
Holger Maul
Keyword(s):  
Preterm Birth ◽  
Low Dose ◽  
Randomized Study ◽  
Preterm Births ◽  
Spontaneous Preterm Birth ◽  
Dose Aspirin ◽  
Nulliparous Women ◽  
Low Dose Aspirin ◽  
Secondary Analyses ◽  
Double Blinded

Abstract Background The rate of preterm births in Germany is 8.6%, which is very high compared to other European countries. As preterm birth contributes significantly to perinatal morbidity and mortality rates, the existing prevention strategies need to be optimized and expanded further. About ⅔ of all women with preterm birth have preterm labor or premature rupture of membranes. They are bracketed together under the term “spontaneous preterm birth” as opposed to iatrogenic preterm birth, for example as a consequence of preeclampsia or fetal growth retardation. Recent studies suggest that low-dose aspirin does not just reduce the rate of iatrogenic preterm births but can also further reduce the rate of spontaneous preterm births. This review article presents the current state of knowledge. Method A selective literature search up until April 2020 was done in PubMed, using the terms “randomized trial”, “randomized study”, “spontaneous preterm birth”, and “aspirin”. Results Secondary analyses of prospective randomized studies on the prevention of preeclampsia with low-dose aspirin show that this intervention also significantly reduced the rate of spontaneous preterm births in both high-risk and low-risk patient populations. The results of the ASPIRIN trial, a prospective, randomized, double-blinded multicenter study carried out in six developing countries, also point in this direction, with the figures showing that the daily administration of 81 mg aspirin starting before 14 weeks of gestation lowered the preterm birth rate of nulliparous women without prior medical conditions by around 11% (11.6 vs. 13.1%; RR 0.89; 95% CI: 0.81 – 0.98, p = 0.012). Conclusion Further studies on this issue are urgently needed. If these confirm the currently available results, then it would be worth discussing whether general aspirin prophylaxis for all pregnant women starting at the latest in 12 weeks of gestation is indicated.

Sign in / Sign up

Export Citation Format

Share Document